Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyReferences
- Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.N Engl J Med. 2017; 377: 613-622
- Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.Am J Obstet Gynecol. 2018; 218: 287-293.e1
- Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial.Lancet. 2009; 374: 979-988
- Hypertension in pregnancy: the management of hypertensive disorders during pregnancy.RCOG Press, London2010
- 743. Summary: low-dose aspirin use during pregnancy.Obstet Gynecol. 2018; 132: 254-256
- Competing risks model in screening for preeclampsia by maternal characteristics and medical history.Am J Obstet Gynecol. 2015; 213: 62.e1-62.e10
- Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE.Ultrasound Obstet Gynecol. 2018; 51: 743-750
- Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia.Ultrasound Obstet Gynecol. 2007; 30: 742-749
- Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia.Ultrasound Obstet Gynecol. 2008; 32: 732-739
- First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia.Ultrasound Obstet Gynecol. 2009; 33: 23-33
- Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach.J Hum Hypertens. 2010; 24: 104-110
- Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.Ultrasound Obstet Gynecol. 2010; 35: 662-670
- Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.Prenat Diagn. 2011; 31: 66-74
- Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting.Am J Obstet Gynecol. 2013; 208: 203.e1-203.e10
- Prediction of preeclampsia utilizing the first trimester screening examination.Am J Obstet Gynecol. 2014; 211: 514.e1-514.e7
- First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors.Prenat Diagn. 2015; 35: 183-191
- A competing risks model in early screening for preeclampsia.Fetal Diagn Ther. 2012; 32: 171-178
- Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.Fetal Diagn Ther. 2013; 33: 8-15
- Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation.Am J Obstet Gynecol. 2016; 214: 103.e1-103.e12
- Model-based screening by risk with application to Down’s syndrome.Stat Med. 1992; 11: 257-268
- The statistical analysis of failure time data.Wiley & Sons; 2002, Hoboken, NJ2002
- Hidden high rate of preeclampsia in twin compared to singleton pregnancies.Ultrasound Obstet Gynecol. 2017; 50: 88-92
- Competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.Ultrasound Obstet Gynecol. 2017; 50: 501-506
- Validation of competing risks model in screening for pre-eclampsia in twin pregnancy by maternal factors.Ultrasound Obstet Gynecol. 2019; 53: 649-654
- Revised competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.Ultrasound Obstet Gynecol. 2019; 54: 617-624
- Uterine artery pulsatility index at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 565-572
- Mean arterial pressure at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 573-579
- Maternal serum placental growth factor at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 472-477
- Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 478-483
- Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks’ gestation.Am J Obstet Gynecol. 2016; 214: 619.e1-619.e17
- Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks’ gestation.Am J Obstet Gynecol. 2016; 215: 87.e1-87.e17
- Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks’ gestation.Ultrasound Obstet Gynecol. 2016; 48: 72-79
- Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy: report of UK collaborative study on alpha-fetoprotein in relation to neural-tube defects.Lancet. 1977; 1: 1323-1332
- Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history.Ultrasound Obstet Gynecol. 2015; 45: 689-697
- Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history.Ultrasound Obstet Gynecol. 2015; 45: 698-706
- Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history.Ultrasound Obstet Gynecol. 2015; 45: 591-598
- Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history.Ultrasound Obstet Gynecol. 2015; 45: 584-590
- Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation.Ultrasound Obstet Gynecol. 2017; 49: 751-755
- Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation.Ultrasound Obstet Gynecol. 2018; 52: 186-195
- Predictive performance of the competing risk model in screening for preeclampsia.Am J Obstet Gynecol. 2019; 220: 199.e1-199.e13
- Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit.Am J Obstet Gynecol. 2018; 218: 612.e1-612.e6
- Contingent screening for preterm pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 554-559
- Two-stage screening for preterm preeclampsia at 11-13 weeks’ gestation.Am J Obstet Gynecol. 2019; 220: 197.e1-197.e7
- Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks’ gestation.Ultrasound Obstet Gynecol. 2017; 50: 367-372
- Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks’ gestation.Ultrasound Obstet Gynecol. 2018; 52: 365-372
- Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks’ gestation.Ultrasound Obstet Gynecol. 2017; 49: 194-200
- Proposed clinical management of pregnancies after combined screening for preeclampsia at 35-37 weeks’ gestation.Ultrasound Obstet Gynecol. 2017; 50: 383-387
- Screening for preeclampsia at 35–37 weeks’ gestation.Ultrasound Obstet Gynecol. 2018; 52: 501-506
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt-11) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia.J Clin Invest. 2003; 111: 649-658
- Circulating angiogenic factors and the risk of pre-eclampsia.N Engl J Med. 2004; 350: 672-683
- Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of pre-eclampsia.J Matern Fetal Neonatal Med. 2011; 24: 1187-1207
- Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays.Am J Obstet Gynecol. 2011; 205: 469.e1-469.e8
- The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients.Am J Obstet Gynecol. 2012; 206: 58.e1-58.e8
- Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study.Circulation. 2013; 128: 2121-2131
- Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Am J Obstet Gynecol. 2013; 208: 287.e1-287.e15
- Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation.Fetal Diagn Ther. 2014; 35: 240-248
- Predictive value of the sFlt-1:PlGF ratio in women with suspected pre-eclampsia.N Engl J Med. 2016; 374: 13-22
- A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.Hypertens Pregnancy. 2016; 35: 295-305
- Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio >38: comparison of performance at 31-34 vs 35-37 weeks’ gestation.Ultrasound Obstet Gynecol. 2017; 49: 209-212
- Prediction of imminent preeclampsia at 35-37 weeks gestation.Am J Obstet Gynecol. 2019; 220: 584.e1-584.e11
Article info
Publication history
Footnotes
This work was supported by grants from the Fetal Medicine Foundation (Charity No: 1037116).
The Fetal Medicine Foundation had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
The authors report no conflict of interest.
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectLinked Article
- How to calculate the risk of preeclampsia in women with a history of positive screeningAmerican Journal of Obstetrics & GynecologyVol. 223Issue 2
- PreviewWith the current demonstration of the benefits of aspirin initiated in early pregnancy to prevent the most severe and preterm forms of preeclampsia, there is a growing interest for the prediction of preterm preeclampsia in the first trimester of pregnancy.1 In the review by Wright et al,2 the authors reported that approximately 90% of women who will develop early preeclampsia could be identified using a competing risks approach in the first trimester of pregnancy, with a false-positive rate of 10%.
- Full-Text
- Preview